Lymphoma and Genomics Research Programme, IOR Institute of Oncology Research, Bellinzona, Switzerland.
Br J Haematol. 2013 Oct;163(2):194-204. doi: 10.1111/bjh.12515. Epub 2013 Aug 21.
In a fraction of patients, chronic lymphocytic leukaemia (CLL) can transform to Richter syndrome (RS), usually a diffuse large B-cell lymphoma (DLBCL). We studied genome-wide promoter DNA methylation in RS and clonally related CLL-phases of transformed patients, alongside de novo DLBCL (of non-germinal centre B type), untransformed-CLL and normal B-cells. The greatest differences in global DNA methylation levels were observed between RS and DLBCL, indicating that these two diseases, although histologically similar, are epigenetically distinct. RS was more highly methylated for genes involved in cell cycle regulation. When RS was compared to the preceding CLL-phase and with untransformed-CLL, RS presented a higher degree of methylation for genes possessing the H3K27me3 mark and PRC2 targets, as well as for gene targets of TP53 and RB1. Comparison of the methylation levels of individual genes revealed that OSM, a stem cell regulatory gene, exhibited significantly higher methylation levels in RS compared to CLL-phases. Its transcriptional repression by DNA methylation was confirmed by 5-aza-2'deoxycytidine treatment of DLBCL cells, determining an increased OSM expression. Our results showed that methylation patterns in RS are largely different from de novo DLBCL. Stem cell-related genes and cell cycle regulation genes are targets of DNA methylation in RS.
在少数患者中,慢性淋巴细胞白血病(CLL)可转化为里希特综合征(RS),通常为弥漫性大 B 细胞淋巴瘤(DLBCL)。我们研究了 RS 和转化患者克隆相关的 CLL 期、新发性非生发中心 B 型 DLBCL、未转化 CLL 和正常 B 细胞的全基因组启动子 DNA 甲基化。RS 和 DLBCL 之间观察到的总体 DNA 甲基化水平差异最大,表明这两种疾病虽然组织学上相似,但在表观遗传学上是不同的。RS 在细胞周期调控基因的甲基化程度更高。当 RS 与之前的 CLL 期和未转化 CLL 进行比较时,RS 具有更高程度的 H3K27me3 标记和 PRC2 靶基因以及 TP53 和 RB1 基因靶标的甲基化,这表明 RS 具有更高程度的甲基化。个别基因甲基化水平的比较表明,OSM,一种干细胞调节基因,在 RS 中比 CLL 期表现出更高的甲基化水平。通过 5-氮杂-2'-脱氧胞苷处理 DLBCL 细胞证实了其转录抑制作用,确定了 OSM 表达增加。我们的研究结果表明,RS 的甲基化模式与新发性 DLBCL 有很大的不同。RS 中干细胞相关基因和细胞周期调控基因是 DNA 甲基化的靶基因。